ConductScience.org, home

Trial · NCT03583372

Participant flow12

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTED40 Weeks Vibegron 75 mg92
Overall StudySTARTED52 Weeks Vibegron 75 mg182
Overall StudySTARTED40 Weeks Tolterodine ER 4 mg91
Overall StudySTARTED52 Weeks Tolterodine ER 4 mg141
Overall StudyCOMPLETED40 Weeks Vibegron 75 mg79
Overall StudyCOMPLETED52 Weeks Vibegron 75 mg156
Overall StudyCOMPLETED40 Weeks Tolterodine ER 4 mg72
Overall StudyCOMPLETED52 Weeks Tolterodine ER 4 mg123
Overall StudyNOT COMPLETED40 Weeks Vibegron 75 mg13
Overall StudyNOT COMPLETED52 Weeks Vibegron 75 mg26
Overall StudyNOT COMPLETED40 Weeks Tolterodine ER 4 mg19
Overall StudyNOT COMPLETED52 Weeks Tolterodine ER 4 mg18

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03583372/flow